The combined action of tyrosine kinase inhibitors (#TKIs) on #thyroid gland function & peripheral deiodinases generates a unique phenotype of primary #hypothyroidism characterised by increased TSH concentrations & a reduced T3 to T4 ratio www.thelancet.com/journals/lan... #MedSky #EndoSky #OncSky

Canadian Obesity guidelines vs. the Lancet Commission: Beverly Tchang, MD, unpacks differences in defining and treating obesity. 🎥 Watch here: www.docwirenews.com/post/obesity...

📊 mweintraubmd.bsky.social reviews ATTAIN-1 & ACHIEVE-1: oral GLP-1 #orforglipron shows weight loss & CV benefit but falls short of injectables. Caution urged on efficacy. @nyulangone.bsky.social 🔗 www.docwirenews.com/post/orforgl...

GLP-1 RAs: Big benefits, small GI risks. 📊 +2 cholelithiasis & +4 GERD cases per 1,000 patients. No rise in pancreatitis or bowel obstruction. Dr. Cho Han Chiang explains how to weigh the trade-offs. 🎥 Watch here: www.docwirenews.com/post/balanci...

New research out of @soleimanpourlab.bsky.social links beta cell failure in T2D to mitochondrial—not ER—protein misfolding. Boosting LONP1 protected cells & restored insulin function, pointing to a novel therapeutic path. 🎥 Watch: www.docwirenews.com/post/targeti...

🚨 New GLP-1 pill shows big results: @elilillyandcompany.bsky.social's once-daily oral #orforglipron led to up to 27.3 lbs weight loss in 72 weeks in phase 3 #ATTAIN1, with improvements in heart risk markers. A potential game-changer for obesity care. docwirenews.com/post/lillys-... #Obesity #GLP1

🚨 Once-weekly semaglutide led to major weight loss & improved glucose control in adults with #T1D + obesity—without added risk. ✅ -8.8 kg weight ✅ ↑ time-in-range ✅ No ↑ in severe hypo or DKA Big step forward in #T1D care. 🔗 www.docwirenews.com/post/once-we... #diabetes #GLP1 #semaglutide @nejm.org